Behind the antibody cocktail rush in India's Covid-19 wave, profits for hospitals and pharma firms

On December 16, Regeneron said its cocktail drug had diminished potency against Omicron. But 13 days later, Cipla held a webinar to promote its use in India.

Related Keywords

United States ,Delhi ,India ,Mumbai ,Maharashtra ,United Kingdom ,Ambajogai ,Anant Waibase ,Sanjay Nagral ,Eli Lilly ,Jaideep Gogtay ,Mahadev Waibase ,Sudhakar Shinde ,Regeneron Regen ,Altaf Khan ,India Central Drugs Standards Control Organisation ,National Institute Of Health ,Indian Council Of Medical Research ,National Health Service ,World Health Organisation On ,Cipla ,Navi Mumbai ,Kopar Khairane ,Central Drugs Standards Control Organisation ,World Health Organisation ,National Institute ,Indian Council ,Medical Research ,Health ,Umbai Third Wave Omicron Antibody Therapy Treatment ,Micron Regen Cov Effective ,Onoclonal Antibody Treatment Omicron Effectiveness ,Onoclonal Antibody Drug Cocktail Cost ,Ntibody Cocktail Treatments ,Covid Mumbai ,S Antibody Cocktail Effective ,Egencov India Price ,